NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024
Reid M. Ness(Breast Cancer Research Foundation), Vaishnavi Sambandam(National Comprehensive Cancer Network), Michael J. Hall(Université Paris Cité), Folasade P. May(University of California, Los Angeles), Mark Friedman(Policy Analysis (United States)), Arnold J. Markowitz(Memorial Sloan Kettering Cancer Center), Rachel B. Issaka(Mayo Clinic in Florida), Peter Vu(UC San Diego Health System), Carly J. Cassara(National Comprehensive Cancer Network), Kinga Skowron Olortegui(University of Chicago Medicine Comprehensive Cancer Center), Kathryn Glaser(Roswell Park Comprehensive Cancer Center), Bryson W. Katona(Washington University in St. Louis), Shrinivas Bishu(University of Michigan), Gregory S. Cooper(University Hospitals Case Medical Center), Lyen C. Huang(University of Utah), Xavier Llor(Yale Cancer Center), Trilokesh D. Kidambi(City Of Hope National Medical Center), Robert J. Mayer(CancerCare), Shajan Peter(University of Colorado Cancer Center), Peter P. Stanich(The Ohio State University Wexner Medical Center), Mohammad Ali Abbass(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Elizabeth H. Wood(University of Tennessee Health Science Center), Laura Porter(Georgetown University), Joseph Marsano(UC Davis Comprehensive Cancer Center), Jennifer K. Maratt(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), David Fudman(Southwestern Medical Center), Jonathan P. Terdiman(UCSF Helen Diller Family Comprehensive Cancer Center), Christopher T. Chen(Cancer Institute (WIA)), Audrey J. Lazenby(Susan Thompson Buffett Foundation), Dayna S. Early, Francis M. Giardiello(Sidney Kimmel Cancer Center), Mehnaz Shafi(The University of Texas MD Anderson Cancer Center), Swati Patel(University of Colorado Anschutz Medical Campus), S Gurudu(WinnMed), Jennifer M. Weiss
Cited by 42
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k